EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: Blood and bone marrow dosimetry in differentiated thyroid cancer therapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 7, 2008, Pages 1405-1412

  Lassmann, Michael ^a,d   Hänscheid, Heribert ^a   Chiesa, Carlo ^b   Hindorf, Cecilia ^c   Flux, Glenn ^c   Luster, Markus ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d NONE   (Germany)

Author keywords

Dosimetry; SOP; Thyroid cancer

Indexed keywords

RECOMBINANT THYROTROPIN;

BONE MARROW CELL; BONE MARROW TOXICITY; CALCULATION; CELL DIFFERENTIATION; DIAGNOSTIC VALUE; DOSE CALCULATION; DOSIMETRY; MATHEMATICAL COMPUTING; NONHUMAN; PRACTICE GUIDELINE; RADIATION ABSORPTION; RADIOIODINATION; REPRODUCIBILITY; REVIEW; RISK BENEFIT ANALYSIS; STANDARD; THYROID CANCER;

ADVISORY COMMITTEES; ASSOCIATION; BLOOD; BONE MARROW; EUROPE; HUMANS; IODINE RADIOISOTOPES; NUCLEAR MEDICINE; RADIOMETRY; RADIOPHARMACEUTICALS; SODIUM IODIDE; THYROID NEOPLASMS;

EID: 45049085218     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0761-x     Document Type: Review

References (25)

1. Benua RS, Cicale NR, Sonenberg M, Rawson RW. Relation of radioiodine dosimetry to results and complications in treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962;87:171-82.
2. Benua RS, Leeper RD. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. Frontiers in thyroidology, vol 2. New York: Plenum Medical; 1986. p. 1317-21.
3. Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hänscheid H, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003;30:1371-7.
4. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648-54.
5. Schlumberger M, Pacini F. Thyroid tumors. 5th ed. Paris: Editions Nucléon; 2003.
6. Schober O, Gunter HH, Schwarzrock R, Hundeshagen H. Long-term hematologic changes caused by radioiodine treatment of thyroid cancer I. Peripheral blood changes. Strahlenther Onkol 1987;163:464-74.
7. Gunter HH, Schober O, Schwarzrock R, Hundeshagen H. Long-term hematologic changes caused by radioiodine treatment of thyroid cancer. II. Bone marrow changes including leukemia. Strahlenther Onkol 1987;163:475-85.
8. Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid. 2002;12:121-14.
9. 124I PET and 3-dimensional internal dosimetry software. J Nucl Med 2007;48:143-9.
10. Sgouros G. Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer. J Nucl Med 2005;46:899-900.
11. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006;47:1587-91.
12. Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998;39:1531-6.
13. Medvedec M. Thyroid stunning in vivo and in vitro. Nucl Med Commun 2005;26:731-5.
14. 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004;4:619-25.
15. Sgouros G, Song H, Ladenson PW, Wahl RL. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med 2006;47:1977-84.
16. Song H, Prideaux A, Du Y, Frey E, Kasecamp W, Ladenson PW, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med 2006;47:1985-94.
17. International Commission on Radiological Protection. ICRP publication 53: Radiation dose to patients from radiopharmaceuticals. Annals of the ICRP, vol 18. Oxford: Pergamon; 1994.
18. Chittenden SJ, Pratt BE, Pomeroy K, Black P, Long C, Smith N, et al. Optimization of equipment and methodology for whole body activity retention measurements in children undergoing targeted radionuclide therapy. Cancer Biother Radiopharm 2007;22:243-9.
19. Akabani G, Poston JW Sr. Absorbed dose calculations to blood and blood vessels for internally deposited radionuclides. J Nucl Med 1991;32:830-4.
20. Loevinger R, Holt JG, Hine JG. Internally administered radioisotopes. In: Hine JG, Brownell GL, editors. Radiation dosimetry. New York: Academic; 1956. p. 803-75.
21. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-7.
22. 131I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab 1973;36:1143-52.
23. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689-94.
24. Chiesa C, De Agostini A, Ferrari M, Pedroli G, Savi A, Traino AC, et al. Dosimetria nella terapia medico nucleare del carcinoma tiroideo metastatico differenziato: calcolo della dose al midollo emopoietico. Notiziario Associazione Italiana Fisica in Medicina 2006;4:299-307.
25. Traino AC, Ferrari M, Cremonesi M, Stabin MG. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol 2007;52:5231-48.